CStone Pharmaceuticals (STU:PH4) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:PH4 CStone Pharmaceuticals STU:PH4
40 GF Score
Price €0.51
GF Value €0.12
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is CStone Pharmaceuticals Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

STU:PH4
40GF Score
CStone Pharmaceuticals STU:PH4
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is CStone Pharmaceuticals (STU:PH4) Overvalued in 2026?

Based on GuruFocus' analysis, CStone Pharmaceuticals stock appears to be overvalued. The current stock price of €0.51 is trading 322.7% above its estimated GF Value™ of €0.12. GuruFocus considers CStone Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for STU:PH4:

  • Dividends Received:
  • GF Value™: €0.12 vs. price of €0.51 (322.7% above fair value)
  • GF Score™: 40/100 with 7 warning signs

No single metric tells the full story. See the STU:PH4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


CStone Pharmaceuticals Business Description

Other Exchanges CSPHF:USA02616:Hong Kong
Address 218 Xinghu Street, C1 Building, North Block, Suzhou Industrial Park, Suzhou, CHN, 215123
CStone Pharmaceuticals is engaged in developing and commercializing immuno-oncology and molecularly targeted drugs to address unmet medical needs in cancer treatment. The Group has been operating in one reportable segment, being the research and development of high-complex biopharmaceutical products, the sale of pharmaceutical products, and provide license of its IP or commercialisation licenses to customers.
40GF Score

Get the complete analysis for STU:PH4

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.51
Price
€0.12
GF Value